Liquid biopsy is a minimally invasive diagnostic approach that analyzes biomarkers in biofluids, for early disease detection, monitoring, and personalized medicine. This project aims to develop advanced lab-on-chip (LoC) platforms and sensing strategies tailored to different classes of biomarkers, including circulating nucleic acids, proteins, small molecules, and post- translational modifications (PTMs) such as glycosylation. Specific technological solutions will be adopted for each biomarker class, with electrochemical transducers being the primary detection method. These transducers will be enhanced with polymer-nanomaterial nanocomposites to improve sensitivity. When necessary, high-sensitivity transducers such as chiral bound states in the continuum (BIC) or graphene modified transistors will be employed. Biomarkers will be analyzed in biological fluids like serum and cerebrospinal fluid, as well as in extracellular vesicles isolated from these fluids. By integrating microfluidic technology, advanced materials this project will provide a versatile approach to liquid biopsy analysis, enabling early diagnosis, disease monitoring, and personalized treatment.